KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Total Debt (2020 - 2025)

Historic Total Debt for Supernus Pharmaceuticals (SUPN) over the last 9 years, with Q3 2025 value amounting to $11.2 million.

  • Supernus Pharmaceuticals' Total Debt fell 7588.07% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.2 million, marking a year-over-year decrease of 7588.07%. This contributed to the annual value of $47.3 million for FY2024, which is 908.39% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Total Debt of $11.2 million as of Q3 2025, which was down 7588.07% from $30.0 million recorded in Q1 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Total Debt peaked at $424.1 million during Q4 2021, and registered a low of $11.2 million during Q3 2025.
  • Its 5-year average for Total Debt is $100.2 million, with a median of $46.7 million in 2022.
  • Within the past 5 years, the most significant YoY rise in Supernus Pharmaceuticals' Total Debt was 160317.35% (2022), while the steepest drop was 9501.99% (2022).
  • Over the past 5 years, Supernus Pharmaceuticals' Total Debt (Quarter) stood at $424.1 million in 2021, then tumbled by 95.02% to $21.1 million in 2022, then soared by 146.54% to $52.1 million in 2023, then dropped by 9.08% to $47.3 million in 2024, then tumbled by 76.27% to $11.2 million in 2025.
  • Its last three reported values are $11.2 million in Q3 2025, $30.0 million for Q1 2025, and $47.3 million during Q4 2024.